

Supplementary material

The 1,3,5-triazine derivatives as innovative chemical family of 5-HT₆ serotonin receptor agents with therapeutic perspectives for cognitive impairment

Gniewomir Latacz, Annamaria Lubelska, Magdalena Jastrzębska-Więsek, Anna Partyka, Małgorzata Anna Marć, Grzegorz Satała, Daria Wilczyńska, Magdalena Kotańska, Małgorzata Więcek, Katarzyna Kamińska, Anna Wesołowska, Katarzyna Kieć-Kononowicz, Jadwiga Handzlik

Table of contents:

1. MS spectra and MS ion fragment analyses of compound **1** and its metabolites 1
2. MS spectra and MS ion fragment analyses of compound **2** and its metabolites 3
3. MS spectra and MS ion fragment analyses of compound **3** and its metabolites 4
4. MS spectra and MS ion fragment analyses of compound **4** and its metabolites 6
5. UPLC spectra of the reference reaction with HLMs.....8

1. MS spectra and MS ion fragment analyses of compound **1** and its metabolites.




Figure S1. MS spectrum of compound **1** (A) and its MS ion fragment analysis (B).





Figure S2. MS spectrum of compound's 1 metabolite M1 (A) and its MS ion fragment analysis (B).






Figure S3. MS spectrum of compound's 1 metabolite M2 (A) and its MS ion fragment analysis (B).

2. MS spectra and MS ion fragment analyses of compound 2 and its metabolites.

A



B





Figure S4. MS spectrum of compound 2 (A) and its MS ion fragment analysis (B).

A



B




Figure S5. MS spectrum of compound's 2 metabolite M1 (A) and its MS ion fragment analysis (B).




Figure S6. MS spectrum of compound 2 metabolite M2 (A) and its MS ion fragment analysis (B)

3. MS spectra and MS ion fragment analyses of compound 3 and its metabolites.




Figure S7. MS spectrum of compound 3 (A) and its MS ion fragment analysis (B).



A**B**

Figure S8. MS spectrum of compound's 3 metabolite M1 (A) and its MS ion fragment analysis (B).



A**B**

Figure S9 MS spectrum of compound's 3 metabolite M2 (A) and its MS ion fragment analysis (B).





Figure S10 MS spectrum of compound's 3 metabolite M3 (A) and its MS ion fragment analysis (B).

4. MS spectra and MS ion fragment analyses of compound 4 and its metabolites.





Figure S11. MS spectrum of compound 4 (A) and its MS ion fragment analysis (B).









Figure S12 MS spectrum of compound's 4 metabolite M1 (A) and its MS ion fragment analysis (B).



_WERAPAMIL-HMA



2: Diode Array
Range: 2.743e+2

Time	Height	Area	Area%
3.38	2948085	78088.40	12.70
3.92	531129	12608.02	2.05
4.00	2883575	78245.84	12.73
4.54	926834	23059.44	3.75
4.62	1646473	51592.59	8.39
4.95	4438933	144382.67	23.49
5.03	5336654	189578.30	30.84

Figure S16 UPLC spectra of the reaction mixture after 120 min incubation of reference drug verapamil with HLMs.